RP8: Heat Shock Protein That Regulates Cell Processes (G7804)

Target Name: LRP8

NCBI ID: G7804

LRP8

RP8: Heat Shock Protein That Regulates Cell Processes

LRP8 (APOER2) is a protein that is expressed in various tissues throughout the body. It is a member of the superfamily of RNA-binding proteins, known as the LRP-1-like proteins. LRP8 is also known as heat shock protein 2 (Hsp2) and has been identified as a potential drug target and biomarker.

RP8 is expressed in a wide range of tissues, including muscle, heart, brain, and kidney. It is also expressed in various cell types, including cancer cells. LRP8 is known to play a role in various cellular processes, including cell signaling, DNA replication, and stress response.

One of the key functions of LRP8 is its role in the heat shock response. During times of stress, such as exercise or exposure to extreme temperatures, LRP8 helps cells adapt and survive by interacting with various proteins and other biomolecules. This interaction with other proteins is known as post-translational modification (PTM).

RP8 is also involved in the regulation of DNA replication. It has been shown to play a role in the replication of DNA in various cell types, including cancer cells. This suggests that LRP8 may be a useful biomarker for cancer diagnosis and treatment.

In addition to its role in cell signaling and DNA replication, LRP8 is also involved in the regulation of cell growth and differentiation. It has been shown to play a role in the regulation of cell proliferation and the maintenance of stem cell properties.

RP8 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and the production of pro-inflammatory cytokines. This suggests that LRP8 may be a useful target for the development of anti-inflammatory therapies.

In conclusion, LRP8 is a protein that is involved in a wide range of cellular processes that are important for cell survival and function. Its involvement in the heat shock response, DNA replication, cell signaling, and inflammation make it a potential drug target and biomarker. Further research is needed to fully understand the role of LRP8 in various cellular processes and its potential as a drug target.

Protein Name: LDL Receptor Related Protein 8

Functions: Cell surface receptor for Reelin (RELN) and apolipoprotein E (apoE)-containing ligands (PubMed:20223215). LRP8 participates in transmitting the extracellular Reelin signal to intracellular signaling processes, by binding to DAB1 on its cytoplasmic tail. Reelin acts via both the VLDL receptor (VLDLR) and LRP8 to regulate DAB1 tyrosine phosphorylation and microtubule function in neurons. LRP8 has higher affinity for Reelin than VLDLR. LRP8 is thus a key component of the Reelin pathway which governs neuronal layering of the forebrain during embryonic brain development. Binds the endoplasmic reticulum resident receptor-associated protein (RAP). Binds dimers of beta 2-glycoprotein I and may be involved in the suppression of platelet aggregation in the vasculature. Highly expressed in the initial segment of the epididymis, where it affects the functional expression of clusterin and phospholipid hydroperoxide glutathione peroxidase (PHGPx), two proteins required for sperm maturation. May also function as an endocytic receptor. Not required for endocytic uptake of SEPP1 in the kidney which is mediated by LRP2 (By similarity). Together with its ligand, apolipoprotein E (apoE), may indirectly play a role in the suppression of the innate immune response by controlling the survival of myeloid-derived suppressor cells (By similarity)

The "LRP8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRP8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets